News

The research collaboration will advance the development of the French firm’s lead product candidate in AML, called UCART123. The deal will combine Weill Cornell’s expertise and resources in

Orphan drug status will provide the company with certain financial benefits such as tax credits for clinical trials, and waiver of prescription drug user fee for the marketing

The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat

The intellectual property related to the panel will also be obtained by the company. Upon execution of the license, Genmab will make a one-time $4m licensing payment to

The recommendation for this combination follows a review by the NHS and Care Excellence (NICE). The combination therapy is indicated for patients with non-small cell lung cancer (NSCLC)

Perrigo will acquire rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. Novartis’s cold sore management products in the EEA and cold and

Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government’s repository of critical medical supplies for biowarfare preparedness. Anthim has been developed under

Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology.

The trial met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001). The observed 50 percent reduction in fractures between